Journal of Clinical Oncology, Vol 2, 1115-1120, Copyright © 1984 by American Society of Clinical Oncology

ARTICLES

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine

LJ Laubenstein, RL Krigel, CM Odajnyk, KB Hymes, A Friedman-Kien, JC Wernz and FM Muggia

An epidemic of disseminated Kaposi's sarcoma in male homosexuals has recently been described. Forty-one evaluable patients with epidemic Kaposi's sarcoma were treated with etoposide. The majority of these patients had early stage disease, no prior opportunistic infections, and no prior therapy. Twelve patients (30%) achieved complete remission, 19 (46%) partial remission, and ten (24%) no response. With follow-up time to 31 months, the median response duration is nine months. The median survival of patients with complete and partial remissions has not been reached. A combination of doxorubicin (Adriamycin, Adria Laboratories, Columbus, Ohio), bleomycin, and vinblastine (ABV) was used in 31 evaluable patients with epidemic Kaposi's sarcoma. The majority of these patients had late stage disease, prior opportunistic infections, or had failed prior treatment. Seven patients (23%) achieved complete remission, 19 (61%) partial remission, and five (61%) no response. With follow-up time to 24 months, the median response duration is eight months. The projected median survival for all patients treated with ABV is nine months. Both regimens were well tolerated, with an overall response rate of 76% for etoposide and 84% for ABV. However, while successfully treating the Kaposi's sarcoma, the underlying immune deficiency in these patients has persisted. Future treatments of Kaposi's sarcoma will need to focus on reversing the underlying immune incompetence as well as controlling the malignant manifestations of Kaposi's sarcoma arising in relation to the acquired immune deficiency syndrome.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Stebbing, A. Wildfire, S. Portsmouth, T. Powles, C. Thirlwell, P. Hewitt, M. Nelson, S. Patterson, S. Mandalia, F. Gotch, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations Ann. Onc., November 1, 2003; 14(11): 1660 - 1666. [Abstract] [Full Text] [PDF]

				S. R. Evans, S. E. Krown, M. A. Testa, T. P. Cooley, and J. H. Von Roenn Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An AIDS Clinical Trials Group Clinical Study J. Clin. Oncol., August 1, 2002; 20(15): 3236 - 3241. [Abstract] [Full Text] [PDF]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				A. Tulpule, D. T. Scadden, B. M. Espina, S. Cabriales, W. Howard, K. Shea, and P. S. Gill Results of a Randomized Study of IM862 Nasal Solution in the Treatment of AIDS-Related Kaposi’s Sarcoma J. Clin. Oncol., February 14, 2000; 18(4): 716 - 716. [Abstract] [Full Text] [PDF]

				P. S. Gill, A. Tulpule, B. M. Espina, S. Cabriales, J. Bresnahan, M. Ilaw, S. Louie, N. F. Gustafson, M. A. Brown, C. Orcutt, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi's Sarcoma J. Clin. Oncol., June 1, 1999; 17(6): 1876 - 1876. [Abstract] [Full Text] [PDF]

				G. M. Wool AIDS-Related Malignancies Oncologist, August 1, 1998; 3(4): 279 - 283. [Full Text]

				S. Miles, O Martinez-Maza, A Rezai, L Magpantay, T Kishimoto, S Nakamura, S. Radka, and P. Linsley Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells Science, March 13, 1992; 255(5050): 1432 - 1434. [Abstract] [PDF]

				L. D. Kaplan, C. B. Wofsy, and P. A. Volberding Treatment of Patients With Acquired Immunodeficiency Syndrome and Associated Manifestations JAMA, March 13, 1987; 257(10): 1367 - 1374. [Abstract] [PDF]

				P. A. VOLBERDING, D. I. ABRAMS, M. CONANT, K. KASLOW, K. VRANIZAN, and J. ZIEGLER Vinblastine Therapy for Kaposi's Sarcoma in the Acquired Immunodeficiency Syndrome Ann Intern Med, September 1, 1985; 103(3): 335 - 338. [Abstract] [PDF]